Search

Search Constraints

You searched for: Author/Creator Goodhand, James R

Search Results

1. Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. (2nd September 2021)

2. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Issue 5 (22nd March 2021)

3. Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment. (4th May 2020)

4. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study. (November 2022)

5. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. (April 2022)

6. Genetic evidence that higher central adiposity causes gastro-oesophageal reflux disease: a Mendelian randomization study. (26th June 2020)

7. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Issue 10 (26th April 2021)

10. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. (February 2023)